Search HDBuzz

Huntington’s disease therapeutics conference 2022 - Day 2

Check out research updates from Day 2 of the 2022 HD Therapeutics Conference #HDTC2022

Dr Sarah Hernandez, Dr Leora Fox, Dr Rachel Harding, and Joel Stanton | June 21, 2022

Artificial intelligence to save the day? How clever computers are helping us understand Huntington’s disease.

Scientists at IBM and the CHDI Foundation have used artificial intelligence to analyse datasets from Huntington’s disease observational trials to model progression of the disease. They hope their findings will help improve clinical trial design.

Dr Rachel Harding | June 21, 2022

Sad news from Novartis: dosing suspended in VIBRANT-HD trial of branaplam

HDBuzz is saddened to share the news that the VIBRANT-HD trial of the oral huntingtin-lowering drug, branaplam, has been temporarily suspended for the safety of participants.

Dr Leora Fox | August 08, 2022

Serious side effects reported for some people treated with the huntingtin-lowering drug AMT-130, currently in clinical trials

After receiving a high dose of uniQure’s gene therapy for Huntington’s disease, a few patients experienced serious side effects, but are now recovering. HDBuzz explores what this means for the experimental huntingtin-lowering drug, AMT-130.

Dr Sarah Hernandez and Dr Rachel Harding | August 29, 2022

Hereditary Disease Foundation (HDF) conference 2022 – Day 2

Read updates from clinical trials and scientific research on Huntington’s disease from Day 2 of the 2022 HDF Milton Wexler Biennial Symposium #HDF2022

Dr Leora Fox, Dr Rachel Harding, and Dr Sarah Hernandez | August 31, 2022

Hereditary Disease Foundation (HDF) conference 2022 – Day 1

Read updates from clinical trials and scientific research on Huntington’s disease from Day 1 of the 2022 HDF Milton Wexler Biennial Symposium #HDF2022

Dr Rachel Harding and Dr Sarah Hernandez | August 31, 2022

Hereditary Disease Foundation (HDF) conference 2022 – Day 3

Read updates from clinical trials and scientific research on Huntington’s disease from Day 3 of the 2022 HDF Milton Wexler Biennial Symposium #HDF2022

Dr Rachel Harding, Dr Leora Fox, Dr Sarah Hernandez, and Dr Jeff Carroll | September 01, 2022

Hereditary Disease Foundation (HDF) conference 2022 – Day 4

Read updates from clinical trials and scientific research on Huntington’s disease from Day 4 of the 2022 HDF Milton Wexler Biennial Symposium #HDF2022

Dr Sarah Hernandez and Dr Rachel Harding | September 02, 2022

Focusing in on fibrils; scientists give us a glimpse of huntingtin protein clumps

Scientists have used powerful microscopes to look at sticky fragments of the Huntington’s disease protein, shedding light on these structures which are thought to drive the disease

Dr Rachel Harding | September 08, 2022

Forward momentum for Roche and Wave in latest news about huntingtin-lowering trials

Two companies developing medicines for Huntington’s disease announced news about their huntingtin-lowering drugs. Let’s talk about the history and the caveats surrounding these hopeful pieces of news.

Dr Jeff Carroll and Dr Leora Fox | September 30, 2022

You can also read About HDBuzz for information on HDBuzz or try your search on a search engine.